-
公开(公告)号：US20110279931A1
公开(公告)日：2011-11-17
申请号：US13130776
申请日：2009-11-25
申请人： Masatsugu Nakamura
发明人： Masatsugu Nakamura
IPC分类号： H02H9/02
CPC分类号： H04M1/72522 , G01M3/16 , G01N27/223 , G06F1/1626 , G06F1/1635 , H04B1/0466 , H04M1/18
摘要： Disclosed is an electronic device capable of controlling a power supply interrupt according to the state of water leakage. A portable telephone (1) is equipped with a water leakage detection unit (60) that detects a physical quantity which changes according to the state of water leakage and a CPU (49) that interrupts a power supply in response to the detection result from the water leakage detection unit (60). When the electrostatic capacity detected by the water leakage detection unit (60) is greater than or equal to a threshold value A and less than a threshold value B, the CPU (49) continues to interrupt the power supply until a time T1 elapses, and when the electrostatic capacity detected by the water leakage detection unit (60) is equal to or greater than the threshold value B, said CPU continues to interrupt the power supply until a time T2 which is longer than the time T1 elapses.
摘要翻译： 公开了能够根据漏水状态来控制电源中断的电子装置。 便携式电话（1）配备有漏水检测单元（60），其检测根据漏水状态而变化的物理量，以及响应于来自所述检测结果的中断电源的CPU（49） 漏水检测单元（60）。 当由漏水检测单元（60）检测到的静电电容大于或等于阈值A且小于阈值B时，CPU（49）继续中断电源直到时间T1过去，并且 当由漏水检测单元（60）检测到的静电容量等于或大于阈值B时，所述CPU继续中断电源，直到经过时间T1的时间T2为止。
-
公开(公告)号：US20110059897A1
公开(公告)日：2011-03-10
申请号：US12804773
申请日：2010-07-29
申请人： Teruo Nishida , Makoto Inui , Masatsugu Nakamura
发明人： Teruo Nishida , Makoto Inui , Masatsugu Nakamura
CPC分类号： A61K38/30 , A61K9/0048 , C07K5/1013 , C07K5/1016 , C07K14/65
摘要： A therapeutic method for treating a skin wound involving administering to a patient in need thereof a composition containing pharmaceutically effective amounts of the following components: (1) a peptide consisting of the amino acid sequence represented by Ser-Ser-Ser-Arg (SEQ ID NO: 1) or pharmaceutically acceptable salts thereof and (2) a peptide consisting of the amino acid sequence represented by Phe-Gly-Leu-Met-NH2 (SEQ ID NO: 2) or substance P or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable additive.
摘要翻译： 一种治疗皮肤伤口的治疗方法，包括向有需要的患者施用含有药学有效量的以下成分的组合物：（1）由Ser-Ser-Ser-Arg（SEQ ID NO： （2）由Phe-Gly-Leu-Met-NH 2（SEQ ID NO：2）或物质P表示的氨基酸序列或其药学上可接受的盐，以及 药学上可接受的添加剂。
-
53.发明授权公开(公告)号：US07795222B2
公开(公告)日：2010-09-14
申请号：US11725761
申请日：2007-03-20
申请人： Teruo Nishida , Makoto Inui , Masatsugu Nakamura
发明人： Teruo Nishida , Makoto Inui , Masatsugu Nakamura
CPC分类号： A61K38/30 , A61K9/0048 , C07K5/1013 , C07K5/1016 , C07K14/65
摘要： A method for treating a corneal disorder or for promoting skin wound healing comprising administering to a patient in need thereof a composition containing pharmaceutically effective amounts of (i) a first peptide comprising an amino acid sequence containing the following consecutive amino acids: Ser-Ser-Ser-Arg (SEQ ID NO: 1), or an analog thereof or a pharmaceutically acceptable salt thereof and (ii) a second peptide comprising an amino acid sequence containing the following consecutive amino acids with a terminal —NH2 group: Phe-Gly-Leu-Met-NH2 (SEQ ID NO: 2), or an analog thereof or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
摘要翻译： 一种治疗角膜病症或促进皮肤伤口愈合的方法，包括向有需要的患者施用含有药学有效量的组合物（i）包含含有以下连续氨基酸的氨基酸序列的第一肽：Ser-Ser- Ser-Arg（SEQ ID NO：1）或其类似物或其药学上可接受的盐，和（ii）包含具有末端-NH 2基团的下列连续氨基酸的氨基酸序列的第二肽：Phe-Gly- Leu-Met-NH 2（SEQ ID NO：2）或其类似物或其药学上可接受的盐以及药学上可接受的载体。
-
公开(公告)号：US20090042962A1
公开(公告)日：2009-02-12
申请号：US11918764
申请日：2006-04-21
IPC分类号： A61K31/4184 , A61K31/4178 , A61K31/41 , A61P27/02 , C07D405/14 , C07D403/02
CPC分类号： A61K31/41
摘要： An object of the present invention is to research a therapeutic agent for a keratoconjunctival disorder. A compound represented by the following general formula (1) or a salt thereof exhibits an excellent improving effect on corneal disorder models, and therefore is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis or conjunctivitis. In the formula, the ring Y represents a substituted or unsubstituted nitrogen-containing heterocyclic ring; R1 represents a carboxy group or a substituted or unsubstituted nitrogen-containing 5-membered heterocyclic ring; and R2 and R3 may be the same or different and represent a hydrogen atom, a substituted or unsubstituted alkyl group or a substituted or unsubstituted alkylcarbonyl group. In the formula, X represents
摘要翻译： 本发明的目的是研究一种治疗角化结膜疾病的药物。 由以下通式（1）表示的化合物或其盐对角膜障碍模型显示出优异的改善效果，因此可用作干眼症，角膜溃疡，角膜炎或结膜炎等角膜结膜疾病的治疗剂。 式中，Y表示取代或未取代的含氮杂环; R 1表示羧基或取代或未取代的含氮5元杂环; 并且R 2和R 3可以相同或不同，表示氢原子，取代或未取代的烷基或取代或未取代的烷基羰基。 在该式中，X表示
-
公开(公告)号：US20080070958A1
公开(公告)日：2008-03-20
申请号：US11662233
申请日：2005-09-13
IPC分类号： A61K31/421 , A61K31/192 , A61P27/02
CPC分类号： A61K9/0048 , A61K31/192 , A61K31/421 , A61K31/603
摘要： An object of the present invention is to research a new medicinal use of E-4-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy) benzyloxyimino]-4-phenylbutyric acid, Z-2-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy) benzyloxyimino]-2-(4-phenoxyphenyl)acetic acid, 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy] benzoic acid, 2(S)-methoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl] propionic acid, or a salt thereof. Any of the above-mentioned carboxylic acid compounds and a salt thereof exhibit an excellent improving effect on corneal disorder models and are useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis or filamentary keratitis.
摘要翻译： 本发明的目的是研究E-4- [4-（5-甲基-2-苯基-4-恶唑基甲氧基）苄氧基亚氨基] -4-苯基丁酸Z-2- [4-（ 5-甲基-2-苯基-4-恶唑基甲氧基）苄氧基亚氨基] -2-（4-苯氧基苯基）乙酸，2- [2-丙基-3- [3- [2-乙基-4-（4-氟苯基） 5-羟基苯氧基]丙氧基]苯氧基]苯甲酸，2（S） - 甲氧基-3- [4- [3-（4-苯氧基苯氧基）丙氧基]苯基]丙酸或其盐。 任何上述羧酸化合物及其盐对角膜障碍模型显示出优异的改善作用，并且可用作角膜结膜疾病如干眼，角膜溃疡，角膜炎，结膜炎，浅表点状角膜病，角膜的治疗剂 上皮缺损，结膜上皮缺损，角膜结膜炎西雅卡，上限角膜结膜炎或丝状角膜炎。
-
公开(公告)号：US20070270378A1
公开(公告)日：2007-11-22
申请号：US11597440
申请日：2005-05-27
IPC分类号： A61K31/717 , A61P27/02
CPC分类号： A61K9/0048
摘要： An object of the present invention is to provide an eyedrop which has a relatively low viscosity before instillation but is thickened on the eyeball surface at instillation. The eyedrop containing a viscous agent for ophthalmic use, which comprises a combination of hydroxyethylcellulose and dextran, exhibits a specific and synergistic thickening effect in the coexistence of mucin. Therefore, the eyedrop of the present invention is thickened on the eyeball surface upon contact with mucin in the precorneal tear film at instillation, whereby a desired pharmacological efficacy or refreshing feel can be sustained.
摘要翻译： 本发明的目的是提供一种滴眼剂，其在滴注之前具有相对较低的粘度，而在滴眼时在眼球表面上增稠。 含有用于眼科用途的粘性剂的滴眼剂包含羟乙基纤维素和葡聚糖的组合，在粘蛋白共存中表现出特异性和协同增稠作用。 因此，本发明的眼药水在滴注时与前角膜泪膜中的粘蛋白接触时在眼球表面上增稠，从而可以维持期望的药理功效或清爽感。
-
公开(公告)号：US20070060628A1
公开(公告)日：2007-03-15
申请号：US10576719
申请日：2004-10-22
申请人： Masatsugu Nakamura
发明人： Masatsugu Nakamura
IPC分类号： A61K31/427
CPC分类号： A61K31/427 , C07D417/12
摘要： Object of the present invention is to search a novel pharmaceutical use of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy) benzyl] thiazolidine-2, 4-dione being a condensed heterocyclic compound, or a salt thereof. 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy) benzyl] thiazolidine-2, 4-dione or a salt thereof can exert an excellent effect to promote healing in a dry eye model, and is useful as a therapeutic agent for keratoconjunctival disorders such as dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis and filamentary keratitis.
摘要翻译： 本发明的目的是搜索5- [4-（6-甲氧基-1-甲基-1H-苯并咪唑-2-基甲氧基）苄基]噻唑烷-2,4-二酮的稠合杂环化合物的新型药物用途， 或其盐。 5- [4-（6-甲氧基-1-甲基-1H-苯并咪唑-2-基甲氧基）苄基]噻唑烷-2,4-二酮或其盐可以在干眼模型中发挥促进愈合的优异效果， 可用作干眼症，角膜溃疡，角膜炎，结膜炎，浅表性点状角膜病，角膜上皮缺损，结膜上皮缺损，角膜结膜炎，角膜结膜炎，丝状角膜炎等角膜结膜疾病的治疗剂。
-
公开(公告)号：US06984629B2
公开(公告)日：2006-01-10
申请号：US10297233
申请日：2001-05-30
IPC分类号： A61K31/70
CPC分类号： A61K31/00 , A61K31/7072 , A61K31/7076 , A61K31/7084 , Y10S514/912
摘要： Based on research for compounds that can display a corneal epithelial migration promoting effect in ophthalmology, the present invention provides P2Y receptor agonist corneal epithelial migration promoters, such as phosphoric acid compounds having an adenosyl group, uridyl group, xanthosyl group, guanosyl group, or thymidyl group, or their salts, with excellent corneal epithelial migration promoting effects.
-
59.发明授权Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides 失效泪液分泌促进剂或滴眼剂用于治疗角膜结膜破裂，含有活性成分钠尿素肽公开(公告)号：US06833358B1
公开(公告)日：2004-12-21
申请号：US09787164
申请日：2001-04-09
IPC分类号： A61K3800
CPC分类号： A61K38/2242
摘要： The object of the present invention is to find new effects of natriuretic peptides in an ophthalmological field. The present invention provides eyedrops for promoting lacrimal secretion or for treating keratoconjunctival disorders containing the natriuretic peptide as active ingredient. The natriuretic peptides are atrial natriuretic peptides (ANP), brain natriuretic peptides (BNP) and C-type natriuretic peptides (CNP). Typical examples of the keratoconjunctival disorder are dry eye, corneal erosion and corneal ulcer.
摘要翻译： 本发明的目的是在眼科领域中发现利尿钠肽的新作用。 本发明提供用于促进泪液分泌或用于治疗含有利尿钠肽作为活性成分的角膜结膜疾病的滴眼剂。 利尿钠肽是心钠素（ANP），脑利钠肽（BNP）和C型利钠肽（CNP）。 角膜结膜疾病的典型例子是干眼症，角膜侵蚀和角膜溃疡。
-
公开(公告)号：US06477282B1
公开(公告)日：2002-11-05
申请号：US09213083
申请日：1998-12-16
IPC分类号： G06K932
CPC分类号： H04N1/3935 , G06T3/4007 , G06T3/403 , G06T7/12 , G06T2207/10008 , G06T2207/30176
摘要： The image forming device according to the present invention performs resolution conversion processing or scaling processing of a binary image and outputs a processed image. The present image forming device is provided with an edge detecting section, which, during resolution conversion or scaling of the binary image, detects edges of the image and detects lengths and shapes of the edges, and with an interpolated/skipped line producing section, which performs resolution conversion processing or scaling processing based on the lengths and shapes of edges detected by the edge detecting section.
摘要翻译： 根据本发明的图像形成装置执行二值图像的分辨率转换处理或缩放处理，并输出处理后的图像。 本图像形成装置设置有边缘检测部分，其在二进制图像的分辨率转换或缩放期间检测图像的边缘并检测边缘的长度和形状以及内插/跳过线产生部分，其中 基于由边缘检测部检测的边缘的长度和形状执行分辨率转换处理或缩放处理。
-
-
-
-
-
-
-
-
-
搜索结果
63 条记录 (耗时 0.022 秒)
